Expertise in
4
conditions

Anil K. D'cruz

Mumbai, MH, IN 
Expertise in
4
conditions
Mumbai, MH, IN 

Overview

Anil D'cruz practices practicing medicine in Mumbai, India.

Mr. D'cruz is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Tongue Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Thyroid Cancer, Laryngectomy, and Thyroidectomy.

He is actively involved in clinical research, co-authoring 171 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Mumbai, MH, India
Other Locations
Navi Mumbai, MH, India
Chennai, TN, India
India
Head Neck Services, Parel, JK 400012, India
Department Of Head And Neck Oncology, Tata, UP, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST)
Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST)
Enrollment Status: Completed
Publish Date: January 16, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
Phase II Randomized Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers.
Phase II Randomized Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers.
Enrollment Status: Unknown
Publish Date: May 02, 2022
Intervention Type: Radiation, Procedure
Study Phase: Not Applicable
Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study.
Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study.
Enrollment Status: Unknown
Publish Date: April 28, 2022
Intervention Type: Drug, Other
Study Drugs: Celecoxib, Erlotinib
Study Phase: Phase 2
View 2 Less Clinical Trials

171 Total Publications

Emerging Treatments and Novel Modalities in Head and Neck Cancers.
Emerging Treatments and Novel Modalities in Head and Neck Cancers.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: June 02, 2026

Frequently Asked Questions about Anil K. D'cruz

Is Anil K. D'cruz a top-rated expert for Tongue Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Anil K. D'cruz is classified as an Distinguished expert for Tongue Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anil K. D'cruz participate in research or clinical trials?

Yes. Anil K. D'cruz has published 171 articles and abstracts on conditions like Tongue Cancer. You can view a list of Anil K. D'cruz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. D'cruz's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile